Two Year Outcomes, Cognitive and Behavioral Markers of Decline in Healthy, Cognitively Normal Older Persons With Global Deterioration Scale Stage 2 (Subjective Cognitive Decline With Impairment)

Two Year Outcomes, Cognitive and Behavioral Markers of Decline in Healthy, Cognitively Normal Older Persons With Global Deterioration Scale Stage 2 (Subjective Cognitive Decline With Impairment) Publisher Pubmed

Reisberg B^{1, 6, 14, 15} ; Torossian C¹ ; Shulman MB^{1, 2} ; Monteiro I¹ ; Boksay I¹ ; Golomb J^{1, 2} ; Benarous FG^{1, 2} ; Ulysse A² ; Oo T² ; Vedvyas A² ; Rao JA² ; Marsh K² ; Kluger A^{1, 7} ; Sangha J¹ Show All Authors

Reisberg B^{1, 6, 14, 15}
Torossian C¹
Shulman MB^{1, 2}
Monteiro I¹
Boksay I¹
Golomb J^{1, 2}
Benarous FG^{1, 2}
Ulysse A²
Oo T²
Vedvyas A²
Rao JA²
Marsh K²
Kluger A^{1, 7}
Sangha J¹
Hassan M¹
Alshalabi M¹
Arain F¹
Shaikh N⁸
Buj M¹
Kenowsky S¹
Masurkar AV²
Rabin L^{9, 15}
Noroozian M^{10, 14}
Sanchezsaudinos MB^{11, 12}
Blesa R^{11, 12, 14}
Auer S¹³
Zhang Y⁵
De Leon M¹
Sadowski M^{1, 2, 3}
Wisniewski T^{1, 2, 4}
Gauthier S^{6, 14}
Shao Y⁵

Show Affiliations

1. Department of Psychiatry, New York University Langone Health, Aging and Dementia Clinical Research Center, NYU Alzheimer's Disease Center, 145 East 32nd Street, New York, 10016, NY, United States
2. Department of Neurology, New York University Langone Health, New York, NY, United States
3. Departments of Biochemistry and Molecular Pharmacology, New York University Langone Health, New York, NY, United States
4. Department of Pathology, New York University Langone Health, New York, NY, United States
5. Division of Biostatistics, Department of Population Health, Department of Environmental Medicine, New York University Langone Health, New York, NY, United States
6. Departments of Neurology and Neurosurgery, Psychiatry, and Medicine, McGill University Research Centre for Studies in Aging, QC, Canada
7. Department of Psychology, Lehman College, City University of New York, New York, NY, United States
8. Kings County Hospital Center, New York, NY, United States
9. Department of Psychology, Brooklyn College, Graduate Center, City University of New York, New York, NY, United States
10. Memory and Behavioral Neurology Division, Roozbeh Hospital, Department of Psychiatry, Tehran University Medical Sciences, Tehran, Iran
11. Department of Neurology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
12. Department of Neurology, Autonomous University of Barcelona, Barcelona, Spain
13. Department for Clinical Neurosciences and Preventive Medicine, Faculty of Health and Medicine, Danube University, Krems, Austria
14. Subjective Cognitive Impairment Working Group, Alzheimer's Disease International (ADI), Austria
15. Subjective Cognitive Decline Initiative (SCD-I), Professional Interest Area (PIA), Alzheimer's Association, Austria

Source: Journal of Alzheimer's Disease Published:2019

Abstract

Background: Little is known with respect to behavioral markers of subjective cognitive decline (SCD), a condition initially described in association with Global Deterioration Scale (GDS) stage 2. Objective: Two-year interval behavioral markers were investigated herein. Methods: Subjects from a published 7-year outcome study of GDS stage 2 subjects were selected. This study had demonstrated a hazard ratio of 4.5 for progression of GDS stage 2, in comparison with GDS stage 1 (no subjective or objective cognitive decline) subjects, after controlling for demographic and temporal variables. Because GDS 2 subjects have previously demonstrated impairment in comparison with healthy persons free of complaints, we herein suggest the terminology SCD(I) for these persons. 98 SCD(I) persons, 63 women and 35 men, mean baseline age, 67.12±8.75 years, with a mean educational background of 15.55±2.60 years, and mean baselineMMSEscores of 28.9±1.24 were followed for 2.13±0.30 years. Results: Observed annual decline on the GDS was 6.701% per annum, very close to a 1986 published estimate. At follow up, the MMSE, and 7 of 8 psychometric tests did not decline significantly. Of 21 Hamilton Depression Scale items, 2 improved and the remainder were unchanged. Anxieties declined from multiple perspectives. The Brief Cognitive Rating Scale (BCRS) declined significantly (p < 0.001), with component declines in Remote memory (p < 0.01), and Functioning/self-care (p = 0.01). Conclusion: SCD(I) persons decline at an annual rate of approximately 6.7%/year from several recent studies. The BCRS assessments and the Digit Symbol Substitution Test can be sensitive measures for future studies of progression mitigation. © 2019 IOS Press and the authors. All rights reserved.

Related Docs

View other Related Docs

1. Alzheimer's Disease: Prototype of Cognitive Deterioration, Valuable Lessons to Understand Human Cognition, Neurologic Clinics (2016)

2. Effect of Memantine Combination Therapy on Symptoms in Patients With Moderate-To-Severe Depressive Disorder: Randomized, Double-Blind, Placebo-Controlled Study, Journal of Clinical Pharmacy and Therapeutics (2017)

3. Memantine Versus Methylphenidate in Children and Adolescents With Attention Deficit Hyperactivity Disorder: A Double-Blind, Randomized Clinical Trial, Iranian Journal of Psychiatry (2015)

4. Simple Neuropsychological Tests May Identify Participants in Whom Aspirin Use Is Associated With Lower Dementia Incidence: The Canadian Study of Health and Aging, American Journal of Alzheimer's Disease and other Dementias (2016)

5. Diagnostic Performance of Mri Radiomics for Classification of Alzheimer's Disease, Mild Cognitive Impairment, and Normal Subjects: A Systematic Review and Meta-Analysis, Aging Clinical and Experimental Research (2023)

6. Study Protocol: Language Profile in Mild Cognitive Impairment: A Prospective Study, Medical Journal of the Islamic Republic of Iran (2019)

7. Using Virtual Reality to Distinguish Subjects With Multiple- But Not Single-Domain Amnestic Mild Cognitive Impairment From Normal Elderly Subjects, Psychogeriatrics (2018)

8. Comparison of Visual Evoked Potential Changes in Patients With Alzheimer, Vascular Dementia and Minimal Cognitive Impairment With Healthy People: A Case-Control Study, Tehran University Medical Journal (2020)

Experts (# of related papers)

View all Related Experts

Maryam Noroozian (4)

Zahra Vahabi (3)

Style	Citing Format
MLA	Reisberg B, et al.. "Two Year Outcomes, Cognitive and Behavioral Markers of Decline in Healthy, Cognitively Normal Older Persons With Global Deterioration Scale Stage 2 (Subjective Cognitive Decline With Impairment)." Journal of Alzheimer's Disease, vol. 67, no. 2, 2019, pp. 685-705.
APA	Reisberg B, Torossian C, Shulman MB, Monteiro I, Boksay I, Golomb J, Benarous FG, Ulysse A, Oo T, Vedvyas A, Rao JA, Marsh K, Kluger A, Sangha J, Hassan M, Alshalabi M, Arain F, Shaikh N, Buj M, ... Shao Y (2019). Two Year Outcomes, Cognitive and Behavioral Markers of Decline in Healthy, Cognitively Normal Older Persons With Global Deterioration Scale Stage 2 (Subjective Cognitive Decline With Impairment). Journal of Alzheimer's Disease, 67(2), 685-705.
Chicago	Reisberg B, Torossian C, Shulman MB, Monteiro I, Boksay I, Golomb J, Benarous FG, et al.. "Two Year Outcomes, Cognitive and Behavioral Markers of Decline in Healthy, Cognitively Normal Older Persons With Global Deterioration Scale Stage 2 (Subjective Cognitive Decline With Impairment)." Journal of Alzheimer's Disease 67, no. 2 (2019): 685-705.
Harvard	Reisberg B et al. (2019) 'Two Year Outcomes, Cognitive and Behavioral Markers of Decline in Healthy, Cognitively Normal Older Persons With Global Deterioration Scale Stage 2 (Subjective Cognitive Decline With Impairment)', Journal of Alzheimer's Disease, 67(2), pp. 685-705.
Vancouver	Reisberg B, Torossian C, Shulman MB, Monteiro I, Boksay I, Golomb J, et al.. Two Year Outcomes, Cognitive and Behavioral Markers of Decline in Healthy, Cognitively Normal Older Persons With Global Deterioration Scale Stage 2 (Subjective Cognitive Decline With Impairment). Journal of Alzheimer's Disease. 2019;67(2):685-705.
BibTex	@article{ author = {Reisberg B and Torossian C and Shulman MB and Monteiro I and Boksay I and Golomb J and Benarous FG and Ulysse A and Oo T and Vedvyas A and Rao JA and Marsh K and Kluger A and Sangha J and Hassan M and Alshalabi M and Arain F and Shaikh N and Buj M and Kenowsky S and Masurkar AV and Rabin L and Noroozian M and Sanchezsaudinos MB and Blesa R and Auer S and Zhang Y and De Leon M and Sadowski M and Wisniewski T and Gauthier S and Shao Y}, title = {Two Year Outcomes, Cognitive and Behavioral Markers of Decline in Healthy, Cognitively Normal Older Persons With Global Deterioration Scale Stage 2 (Subjective Cognitive Decline With Impairment)}, journal = {Journal of Alzheimer's Disease}, volume = {67}, number = {2}, pages = {685-705}, year = {2019} }
RIS	TY - JOUR AU - Reisberg B AU - Torossian C AU - Shulman MB AU - Monteiro I AU - Boksay I AU - Golomb J AU - Benarous FG AU - Ulysse A AU - Oo T AU - Vedvyas A AU - Rao JA AU - Marsh K AU - Kluger A AU - Sangha J AU - Hassan M AU - Alshalabi M AU - Arain F AU - Shaikh N AU - Buj M AU - Kenowsky S AU - Masurkar AV AU - Rabin L AU - Noroozian M AU - Sanchezsaudinos MB AU - Blesa R AU - Auer S AU - Zhang Y AU - De Leon M AU - Sadowski M AU - Wisniewski T AU - Gauthier S AU - Shao Y TI - Two Year Outcomes, Cognitive and Behavioral Markers of Decline in Healthy, Cognitively Normal Older Persons With Global Deterioration Scale Stage 2 (Subjective Cognitive Decline With Impairment) JO - Journal of Alzheimer's Disease VL - 67 IS - 2 SP - 685 EP - 705 PY - 2019 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract